Oncolys BioPharma Inc.
4588
Rank in Stocks
#7210
Oncolys BioPharma Inc. is a biotechnology firm dedicated to the research,... Oncolys BioPharma Inc. is a biotechnology firm dedicated to the research, development, manufacturing, sales, and distribution of oncolytic viruses, pharmaceutical drugs, and diagnostic agents for tumors across Japan, other Asian regions, and the United States. Its robust pipeline features Telomelysin (OBP-301), an oncolytic adenovirus, currently in Phase II clinical trials for the treatment of gastric, gastroesophageal junction, head and neck, and esophageal cancers, and in Phase I trials for hepatocellular carcinoma. Other key developments include OBP-702, a telomerase-specific oncolytic adenovirus in preclinical stages for solid tumors; OBP-2011, also preclinical, targeting SARS-CoV-2 infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed Phase IIb clinical trials for HIV; and OBP-801, a histone deacetylase inhibitor, which is in Phase I clinical trials for solid tumors and preclinical assessment for ophthalmic applications. Additionally, the company is advancing TelomeScan (OBP-401 and OBP-1101), a cancer detection drug designed to identify living circulating tumor cells in cancer patients' blood. Oncolys BioPharma also offers diagnostic medications and inspection services. The company boasts various licensing and collaborative agreements with institutions such as Okayama University, Osaka University, Kyoto Prefectural University of Medicine, Kagoshima University, Astellas Pharma Inc., Yale University, Biologics Consulting Group, Inc., Lonza Houston, Inc., Medigen Biotechnology Corp., and Liquid Biotech USA, Inc. Founded in 2004, Oncolys BioPharma Inc. is based in Tokyo, Japan.
Share Price
$48.23
Last synced: 2026-11-10
Market Cap
$1.42B
Change (1 day)
7.32%
Change (1 year)
683.86%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Oncolys BioPharma Inc. (4588)
Category
Healthcare
Operating Margin for Oncolys BioPharma Inc. (4588)
Operating Margin as of November 2026 TTM: -303.04%
According to Oncolys BioPharma Inc.'s latest financial reports, its current operating margin (TTM) is -303.04%. At the end of 2025 the company had an operating margin of -7,090.55%.
Operating Margin history for Oncolys BioPharma Inc. from 2012 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -303.04% | -95.73% |
| 2025 | -7,090.55% | 32.35% |
| 2024 | -5,357.52% | 74.99% |
| 2023 | -3,061.62% | 2,381.25% |
| 2022 | -123.39% | -45.50% |
| 2021 | -226.39% | -57.53% |
| 2020 | -533.03% | 1,258.73% |
| 2019 | -39.23% | -94.70% |
| 2018 | -740.18% | 57.27% |
| 2017 | -470.63% | -2.57% |
| 2016 | -483.03% | -38.43% |
| 2015 | -784.46% | -72.71% |
| 2014 | -2,874.41% | -94.90% |
| 2013 | -56,395.08% | 158,625.25% |
| 2012 | -35.53% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.13% |
US
|
|
| -149.01% | -99.51% |
US
|
|
| 25.57% | -100.08% |
AU
|
|
| 31.23% | -100.10% |
BE
|
|
| 29.35% | -100.10% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Oncolys BioPharma Inc.'s operating margin
What is Oncolys BioPharma Inc.'s operating margin?
Oncolys BioPharma Inc.'s operating margin is -303.04%, as of Nov 2026.
What was Oncolys BioPharma Inc.'s operating margin in 2025?
In 2025, Oncolys BioPharma Inc.'s operating margin was -7,090.55%, compared with -5,357.52% in 2024.
How has Oncolys BioPharma Inc.'s operating margin changed since 2020?
From 2020 to 2025, Oncolys BioPharma Inc.'s operating margin was highest in 2022 (-123.39%) and lowest in 2025 (-7,090.55%).
How does Oncolys BioPharma Inc.'s operating margin compare with similar companies?
Oncolys BioPharma Inc.'s operating margin (-303.04%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.